

Index

- abnormal uterine bleeding, 108, 113
- acupuncture, 159–160
- adenomyosis
 - effects of the menopause, 108
 - management, 115
 - pathophysiology, 109
- aging
 - and risk of VTE, 185
 - and sexual decline, 104
 - risk factor for CVD, 36
- Albright, Fuller, 58
- alendronate, 76–77
- alternative therapies
 - claims made by proponents, 158
 - common misunderstandings
 - about, 161
 - definition, 157
 - direct risks, 159
 - evidence for effectiveness, 158–159
 - expectations of users, 157–158
 - extent of use for menopausal symptoms, 157
 - indirect risks, 159
 - need for reliable information
 - about, 158, 161
 - problem of evaluating effectiveness, 159–161
 - risk-benefit balance, 159
 - safety issues, 159
- Alzheimer’s disease (AD)
 - costs to the UK health-care system, 91
 - effects of estrogen therapy at menopause, 91–92
 - prevalence and future projections, 91
 - role of estrogen at the menopause, 91
 - role of the cholinergic system, 93
 - role of the dopaminergic system, 94
 - role of the serotonergic system, 94
 - See also* memory.
- American Society of Clinical Oncology (ASCO)
 - guidelines, 143
- American Society of Reproductive Medicine, 198
- androgen therapy
 - adverse events in women, 139–140
 - androgen physiology in women, 137
 - causes of androgen insufficiency in women, 137–138
 - considerations when prescribing for FSD, 140–141
 - description, 136–137
 - DHEA, 136
 - effectiveness in treating FSD, 138–139
 - for female sexual dysfunction (FSD), 137
 - indications for, 137
 - postmenopausal therapies, 136–137
 - role of androgens in female physiology, 136
 - routes of administration for testosterone therapy, 138–139
 - safety considerations for women, 139–140
 - use of testosterone, 136
 - See also* testosterone replacement therapy (TRT).
- androgens, 2
- andropause. *See* male menopause
- androstenedione, 37, 136
- anovulatory cycles, 6, 8, 29, 108
- anti-Müllerian hormone (AMH)
 - assessment of ovarian reserve, 14
 - effects of chemotherapy, 14–17
 - potential role as reproductive biomarker, 6
 - predicting the menopause, 14–17
- anti-ovarian antibodies, 16
- antral follicle count (AFC), 16
- antral follicles, 2
- anxiety
 - cognitive behavior therapy (CBT), 88
- Aristotle, 20
- asoprisnil, 125
- assisted reproduction, 13–14, 16
 - oocyte vitrification, 17–18
- atherosclerosis, 38
- atractylodes in herbal medicine, 22
- atrophic vaginitis
 - definition, 52
 - local estrogen therapies, 48
 - See also* vulvo-vaginal atrophy.
- autoimmune disease
 - and premature ovarian insufficiency (POI), 195
- back pain, 8
 - and osteoporosis, 68
- bazedoxifene, 65, 76, 142, 176
 - tissue selective estrogen complex (TSEC), 145–146
- Beck, Aaron, 87
- biopsychosocial approach, 81, 86–87
- bisphosphonates, 65, 76–77
- black cohosh, 22, 154, 158, 160
- bladder pain syndrome, 103
- bone fracture risk
 - effects of HRT, 207
- bone mineral density (BMD), 67
 - assessment, 68–70
 - benefits and risks of HRT, 62–65

| | | Index | 233 |
|---|--|--|-----|
| dual energy X-ray absorptiometry (DXA), 68–70 | breast density | cardiovascular effects of HRT, | |
| effects of POI, 217 | and breast cancer risk, 175 | 208, 211 | |
| loss of, 9 | and mammographic sensitivity, 175 | effects of progestin component, 43 | |
| prevention of | effects of estrogen/progestin HRT, 130 | influence of HRT formulation and dose, 41–44 | |
| postmenopausal bone loss, 65 | breast tenderness, 8 | influence of route of administration, 41–42 | |
| prophylactic use of HRT, 62–65 | British Menopause Society, 65, 149 | modern view of postmenopausal HRT, 40–41 | |
| protective role of HRT, 59–60 | bupleurum in herbal medicine, 22 | observational studies, 39 | |
| recommendations for maintenance, 62 | Burger, Professor Henry, 27 | preventive use of HRT, 40–43 | |
| bone quality, 67 | calcitonin, 65 | randomized controlled trials (RCTs), 39–40 | |
| bone remodeling | calcitriol, 65 | timing hypothesis, 40–41 | |
| postmenopausal | calcium/vitamin D supplementation, 158 | cardiovascular effects of POI, 217 | |
| osteoporosis, 58 | osteoporosis treatment, 65 | cathepsin K inhibitors, 79 | |
| bone strength, 67 | cancer and HRT | Cerazette™, 165 | |
| bone turnover | case example, 173 | cervical cancer, 170 | |
| role of estrogen, 58–59 | Cancer Prevention Study II, 41 | cervical cancer survivors and HRT, 182 | |
| Botulinum toxin, 50 | cancer screening | chamomile herbal remedy, 22 | |
| brain. <i>See</i> estrogen effects on the brain | problems associated with vulvo-vaginal atrophy, 55 | chemotherapy | |
| brain imaging studies | cancer survivors and HRT, 179 | and premature ovarian insufficiency (POI), 195 | |
| effects of estrogen, 94–97 | breast cancer survivors, 179–180 | assessing risk of early menopause, 16–17 | |
| BRCA1 and BRCA2 mutation carriers | cervical cancer survivors, 182 | effects on AMH levels, 16–17 | |
| and HRT, 177–178 | endometrial cancer survivors, 181 | menopause induced by, 30 | |
| breast cancer risk | gynecologic cancer survivors, 182 | risk of vulvo-vaginal atrophy, 55 | |
| and use of HRT, 26–27, 173–175, 210 | ovarian cancer survivors, 181–182 | Chinese herbal medicine, 22 | |
| BRCA1 and BRCA2 mutation carriers, 177–178 | vaginal cancer survivors, 182 | chocolate cyst, 109, 111 | |
| concerns about HRT (case example), 149 | vulval cancer survivors, 182 | cholesterol, 2 | |
| family history risk factors, 175 | cancer treatments | cholesterol levels | |
| related to the menopausal transition, 9 | and use of local estrogen therapy, 56 | changes at menopause, 36 | |
| risk factors, 173, 175 | cardiovascular disease (CVD) | cholinergic system | |
| risk related to breast density, 175 | healthy lifestyle to help mitigate risk, 39 | role in mood and memory, 99 | |
| risk with hormonal contraception, 167 | menopause as risk factor, 36–37 | chromosomal abnormalities | |
| breast cancer survivors and HRT, 179–180 | preventive strategies, 40–43 | as cause of POI, 194 | |
| breast cancer treatments | risk factors, 36–40 | citalopram, 152–153 | |
| and use of local estrogen therapy, 56 | risk related to menopausal complaints, 38–39 | climacteric | |
| raloxifene, 144 | risk related to menopause, 8–9 | definition, 29 | |
| tamoxifen, 143 | role of estrogens, 37–38 | <i>See also</i> menopausal transition. | |
| tamoxifen interactions with SSRIs, 152–153 | | clonidine, 31, 150–151 | |
| toremifene, 143–144 | | cognition | |
| | | effects of HRT, 208 | |
| | | <i>See also</i> estrogen effects on the brain. | |

| 234 | Index | |
|-----|--|--|
| | cognitive behavior therapy (CBT) case example, 89 definition, 87 for anxiety, 88 for depression, 88 for sleep problems, 88 for vasomotor symptoms, 88–89 cognitive impairment risk effects of POI, 217 colorectal cancer, 170 and HRT, 178, 209 complete procidentia. <i>See</i> pelvic organ prolapse concentration lack of, 8 conjugated equine estrogens (CEE), 42 contraception and premature ovarian insufficiency (POI), 219 contraceptive pill, 94 hormonal contraceptives, 14 contraception at perimenopause barrier methods, 167–168 benefits of contraception, 164–166 combination hormonal methods, 169–171 contraceptive needs, 163–164 contraceptive options, 164 definition of perimenopause, 163 emergency hormonal contraception (EHC), 169 erroneous beliefs about risk of pregnancy, 163 intrauterine device (IUD), 168 non-hormonal methods, 167–168 permanent methods, 164 progestin-only methods, 168–169 reversible contraceptive methods, 167–171 risk of breast cancer, 167 risk of VTE, 166–167 risks associated with later pregnancy, 164 risks of contraception, 166–167 sterilization, 164 transition to menopause management, 171 unintended pregnancy rate, 163 women’s health issues, 171–172 corpus luteum (yellow body), 2 coumestans, 122–123, 153–154 cultural context of menopause, 81–82 cystadenomas, 110–111 cystocoele. <i>See</i> pelvic organ prolapse cytokines role in bone remodeling, 59 dandelion herbal remedy, 22 Danish Nurses Cohort Study, 217 Danish Osteoporosis Prevention Study (DOPS), 43 Danish Osteoporosis Study effects of progestogens in HRT, 133–134 definitions in reproductive aging, 3 degenerative arthritis risk effects of HRT, 207 dehydroepiandrosterone (DHEA), 136 use in vulvo-vaginal atrophy, 56 dehydroepiandrosterone sulfate (DHEA-S) alternative therapy, 159 denosumab, 78–79 dental health and HRT, 209 depression, 31–32 case example, 81, 86–87 cognitive behavior therapy (CBT), 88 effects of estrogen, 93–99 effects of HRT, 207 potential benefits of estrogen at menopause, 98 relationship with vasomotor symptoms, 85–86 risk factors at menopause, 82–85 role of estrogen at the menopause, 91 role of the cholinergic system, 93 role of the dopaminergic system, 94 role of the serotonergic system, 94 dermoid, 111 desogestrel, 165, 168 desvenlafaxine, 103, 153 diabetes risk factor for CVD, 36–37 dietary supplementation risks related to, 159 diethylstilbestrol (DES), 24, 118 differential diagnosis for menopausal symptoms, 30 dihydrotestosterone (DHT), 136 diosgenin, 24 dong quai in herbal medicine, 22 dopaminergic system role in mood and memory, 94 droloxifene, 142 dual energy X-ray absorptiometry (DXA), 68–70 DXA bone densitometry, 65 dyspareunia, 7–8, 52–55, 57, 76, 103 ospermifene treatment, 144–145 early menopause, 85 Early versus Late Intervention Trial with Estradiol (ELITE), 41 ectopic pregnancy, 112 egg donation, 196–202 cost, 202 cycle programming, 200 donor matching, 199–200 egg collection and embryo transfer, 201–202 endometrial development, 200–201 regulation, 196–197 screening of egg donors, 198–199 sources of egg donors, 197–198 success rates, 202 embryo cryopreservation, 18 endometrial ablation, 115 | |

- endometrial cancer, 170
 - and HRT, 175–176, 212
 - risk related to the
 - menopausal transition, 9
- endometrial cancer survivors
 - and HRT, 181
- endometrial carcinoma, 108, 112
- endometrial hyperplasia, 108
 - management, 116
 - pathophysiology, 111–112
- endometrial polyps, 108
 - pathophysiology, 112
- endometrioma, 109, 111
- endometriosis
 - effects of the menopause, 108
 - management, 115–116
 - pathophysiology, 109–110
- endometrium
 - action of progestins, 127–128
- endorphins
 - role in hot flushes, 156
- enterocele. *See* pelvic organ prolapse
- equol, 154
- escitalopram, 153
- Esmya[®], 115
- esophageal cancer
 - and HRT, 179
- Essure[™] system, 164
- estretol (E4), 24, 119
- ESTHER Study, 186, 189
- estradiol (E2), 2, 14, 24, 37
 - esterification for hormone therapy, 24
 - levels during the menopausal transition, 5–6
 - role in the menstrual cycle, 2
 - synthesis for hormone therapy, 24
 - variations in levels at perimenopause, 108
- 17 β -estradiol, 42, 119–121
- estriol (E3), 24, 37, 119
- estrogen
 - development of estrogen treatments, 24
 - effects on neurotransmitters, 8
 - impact on sexual function at menopause, 104
 - local estrogen therapy, 48, 55–56
 - modulation of inflammation, 38
 - modulation of vascular function, 37–38
 - role in Alzheimer's disease (AD), 91
 - role in bone turnover, 58–59
 - role in CVD risk, 37–38
 - role in depression at the menopause, 91
 - role in pelvic organ dysfunction, 46
- estrogen agonists/antagonists. *See* selective estrogen receptor modulators (SERMs)
- estrogen effects on the brain
 - and Alzheimer's disease, 92
 - brain imaging studies, 94–97
 - cholinergic system, 99
 - consequences of acute
 - ovarian steroid suppression, 96
 - dopaminergic system, 94
 - effects on memory, 92
 - estrogen receptors (ERs), 93
 - neuroendocrine studies, 93–94
 - potential benefits at menopause, 98
 - production of estradiol by neurons, 93
 - pseudo-menopause, 96
 - role in depression at menopause, 92–93
 - serotonergic system, 94
- Estrogen in the Prevention of Reinfarction Trial (ESPRIT), 39
- estrogen receptors (ERs), 37–38, 58
 - in the brain, 93
- estrogen response elements (EREs), 58
- estrogen therapies
 - bioidentical estrogen, 123
 - derived from horses, 122
 - derived from plants, 122–123
 - 17 β -estradiol, 119–121
 - estrogens currently used in formulations, 119–121
 - estrogens native to humans, 22
 - formulations and brands
 - available, 119–121
 - history of development, 118–119
 - Premarin[®], 24–25, 27, 118–119, 122
 - transdermal delivery systems, 42, 105, 122
 - with natural estrogens, 119–123
 - See also* hormone replacement therapy (HRT).
- estrogen/progestin regimes in HRT, 128–129
- estrone (E1), 6, 24, 37, 119
 - urine-derived, 118
- ethinyl estradiol, 24, 118
- etonogestrel implant, 168
- European Medicines Authority, 62
- European Prospective Investigation into Cancer and Nutrition, 130
- evening primrose oil, 154
- Evra[™], 171
- exercise interventions
 - effects on vasomotor symptoms, 155
 - walking, 159
 - weight-bearing exercise, 159
- eye health and HRT, 209
- falls risk assessment tools, 68
- Falls Risk for Older People in the Community (FROP-Com) tool, 68
- female sexual dysfunction (FSD), 136
 - androgen therapy, 137
 - considerations when prescribing androgen therapy, 140–141
 - effectiveness of androgen therapy, 138–139
- female sexual function
 - effects of HRT, 206
- fesoterodine, 49
- fetal stage
 - oocyte production, 5
- fiber intake, 158
- fibroids
 - effects of the menopause, 108
 - management, 114–115
 - pathophysiology, 109
- fluoxetine, 31, 152

Cambridge University Press

978-1-107-45182-7 - Managing the Menopause: 21st Century Solutions

Edited by Nick Panay, Paula Briggs and Gab Kovacs

Index

[More information](#)

236

Index

- follicle-stimulating hormone (FSH)
 levels in POI, 215
 secretion and inhibition, 1–2, 5–6
 use of level as screening test, 14
- follicle-stimulating hormone (FSH) receptors, 2
- fracture risk
 effects of HRT, 207
- fracture risk stratification, 70
- FRAX algorithm (WHO), 70
- functional magnetic resonance imaging (fMRI) of the brain, 94–96
- functional reach test, 68
- gabapentin, 31, 153
- gall bladder cancer and HRT, 159
- gall bladder disease and HRT, 213
- Garvan fracture risk calculator, 70
- genetic causes of POI, 194
- ginger in herbal medicine, 22
- ginseng, 159–160
- gonadal dysgenesis, 150
- gonadotropin-releasing hormone (GnRH), 2
- gonadotropin-releasing hormone (GnRH) agonists, 115
- gonadotropins
 secretion and inhibition, 2
- granulosa cells, 2
- gynecological pathology
 abnormal uterine bleeding, 108, 113
- adenomyosis, 108–109, 115
- cancers and HRT, 212
- clinical scenarios and diagnosis, 112–114
- common conditions in the perimenopause, 108
- conditions which are cured by menopause, 108
- cystadenomas, 110–111
- effects of unbalanced sex hormone levels, 108
- endometrial hyperplasia, 108, 111–112, 116
- endometrial polyps, 108, 112
- endometriosis, 108–109, 115–116
- fibroids, 108–109, 114–115
- hysterectomy, 114–116
- improvements in management options, 116
- management options, 114–116
- neuralgias, 116
- ovarian cysts, 108, 110–111, 116
- pelvic floor myalgia, 116
- pelvic mass, 114
- pelvic pain presentation, 112–113
- simple ovarian cysts, 110–111
- solid or complex ovarian cysts, 111
- HABITS Study, 179–180
- headache, 8, 31, 58
- Healy, Dr Bernadine, 25
- Heart and Estrogen Replacement Study (HERS), 39–40
- heart attack in women, 36
- heart attack risk
 and use of HRT, 26–27
- Herbal Alternatives for Menopause Trial (HALT), 154
- herbal medicine, 157
- herbal remedies, 160
- as alternatives to HRT, 24
- for menopausal symptoms, 21–22
- hereditary non-polyposis colorectal cancer, 178
- Hippocrates, 20
- history of the menopause
 association with ovarian function, 22
- association with witchcraft, 21
- consequences of fears about HRT, 27–28
- demand for effective medical treatments, 23–24
- development of bio-identical progesterone, 25
- development of estrogen treatments, 24
- development of HRT, 25
- development of progestogens, 25
- developments in the 19th century, 22
- early accounts, 21–25
- herbal remedies, 21–22
- politics of postmenopausal sexuality, 23–24
- social issues, 23–24
- stigma associated with menopause, 20–21
- surgical ‘cures’, 22
- Victorian attitude, 23
- Women’s Health Initiative (WHI) Study, 25–28
- homeopathy, 159–160
- HORIZON trial, 76
- hormonal regulation of the menstrual cycle, 1–3
- hormone replacement therapy (HRT)
 and bone fractures, 207
- and breast cancer risk, 26–27, 173–175, 210
- and cancer risk, 173
- and cardiovascular disease, 208, 211
- and colorectal cancer, 178, 209
- and degenerative arthritis, 207
- and depression, 207
- and endometrial cancer, 175–176, 212
- and gall bladder disease, 213
- and gynecological cancers, 212
- and lung cancer, 175, 178
- and neurodegenerative disease, 208
- and ovarian cancer, 176–177, 212
- and skin cancers, 179
- and stomach cancer, 209
- and type II diabetes risk, 209
- and upper gastrointestinal tract cancers, 159
- and VTE. *See* venous thromboembolism (VTE) and HRT
- as preventive strategy for CVD, 40–43
- association with incontinence, 48
- bioidentical estrogen, 123
- BRCA1 and BRCA2 mutation carriers, 177–178
- breast cancer survivors, 179–180

- cardiovascular effects, 39–41
cardiovascular effects of
 progestin component, 43
concerns about adverse events, 26–27
concerns about risks, 149
consequences of fears about, 27–28
controversy over
 interpretation of studies, 26–27
dental health, 209
development of, 23
development of lower-dose regimens, 134
effects of smoking, 187
effects of stopping, 27–28
effects on bone density, 59–60, 207
effects on female sexual function, 206
effects on mammographic breast density, 130
effects on memory and cognition, 208
effects on mood disorders, 207
effects on muscle mass and strength, 62
effects on urogenital symptoms, 206
effects on vasomotor symptoms, 206
effects on vulvo-vaginal atrophy, 55
endometrial cancer survivors, 181
estrogen/progestin regimes, 128–129
evidence for effects of progestogens, 130–134
eye health, 209
fears associated with, 24
for cancer survivors, 179–180, 182
formulations and brands available, 119–121
future directions, 28
gynecologic cancer survivors, 182
history of development, 25, 118–119
influence of formulation and dose, 41–42
influence of route of administration, 41–44
Million Women Study (MWS), 26
modern view of postmenopausal HRT, 40–41
non-oral routes of administration, 134
ovarian cancer survivors, 181–182
patients with thrombophilia, 187–188
prophylactic use, 62–65
risk-benefit analysis
 benefits, 205–209
 evaluation of benefits and risks, 62–65
 individualized approach, 214, 205
 influential factors, 205
 risks, 210–213
 women below the age of 60, 213
 women over the age of 60, 214
role in osteoporosis management, 59–60, 74–75, 207
role in premature ovarian insufficiency (POI), 195, 219–220
safety studies, 130–134
search for alternatives to, 24
search for safer methods, 134
skin benefits, 207–208
stroke risk, 211
studies of cardiovascular effects, 39
timing hypothesis for effectiveness, 40–41
weighing VTE risks against benefits, 189–190
with natural estrogens, 119–123
women with personal history of venous thrombosis, 188
See also Women's Health Initiative (WHI) Study.
hot flashes
 duration of symptoms, 30
 mechanism, 30–31
See also vasomotor symptoms.
Household Survey for England Study, 82–83
Huggins, Charles, 228
Human Fertilisation and Embryology Authority (HFEA), UK, 196–198
human papilloma virus (HPV), 170
hypercholesterolemia
 risk factor for CVD, 36
Hypericum perforatum (St John's wort), 22
hypertension
 and the menopausal transition, 8–9
 risk factor for CVD, 36
hypothalamic amenorrhea, 14
hypothalamic-pituitary-ovarian axis, 2, 6
hysterectomy, 108, 114–115
ibandronate, 76–77
idoxifene, 142
incontinence, 52
 conservative management, 48–49
 effects of HRT, 48
 local estrogen therapies, 48
 surgical management, 50
 symptoms, 47
See also stress urinary incontinence; urge urinary incontinence.
Indian Menopause Society, 216
inflammation
 modulation by estrogens, 38
inhibin A, 2
inhibin B, 2, 5–6
 predictive value, 14
injectable DMPA
 contraceptive, 168–169
insomnia associated with the menopause, 31
insulin resistance
 and the menopausal transition, 8–9
 CVD risk factor, 36–37
International Menopause Society, 123, 140
intervertebral discs
 changes after the menopause, 59–62
intrauterine device (IUD), 168
irritability symptom, 8
isoflavones, 31, 122–123, 153–154, 158

| 238 | Index |
|--|---|
| IVF (<i>in vitro</i> fertilization) definition of ovarian reserve, 13 FSH level screening test, 14 | |
| joint pain, 31, 58 | |
| joint stiffness, 8 | |
| Kegel's exercises, 48 | |
| Kennedy, President John F., 228 | |
| Kentera [®] , 49 | |
| Kliefem, 130 | |
| Kronos Early Estrogen Prevention Study (KEEPS), 42 | |
| lactobacilli, 57 | |
| lasofofene, 76, 142 | |
| levonorgestrel, 134 | |
| levonorgestrel intrauterine system (L-IUS), 108, 116, 134, 165–166, 169, 171, 176 | |
| levormeloxifene, 142 | |
| LIBERATE Study, 180 | |
| libido, loss of. <i>See</i> sexual disorders | |
| life expectancy and POI, 216 | |
| lifestyle effects on vasomotor symptoms, 155 influence on CVD risk, 39 | |
| LIFT study, 174 | |
| lignans, 122–123, 153–154, 158 | |
| liquorice herbal remedy, 22 | |
| local estrogen therapies, 105 | |
| lung cancer and HRT, 178, 212 | |
| luteinizing hormone (LH) levels in POI, 215 secretion and inhibition, 1–2, 6 | |
| luteinizing hormone (LH) receptors, 2 | |
| Lynch syndrome, 178 | |
| magnetic resonance spectroscopy (¹ H-MRS) of the brain, 96–97 | |
| male menopause consequences of androgen deficiency, 225–226 consequences of the WHI Study for TRT, 228 | |
| | economic arguments for TRT, 229–231 |
| | emotional issues, 227 |
| | ethical arguments for TRT, 229–231 |
| | factors in testosterone deficiency, 225 |
| | lack of recognition by the medical profession, 223–224 |
| | myths about TRT, 228–231 |
| | negative associations with testosterone, 227–228 |
| | reasons for denial of loss, 114–116 |
| | reasons for opposition to TRT, 227 |
| | testosterone replacement therapy (TRT), 223–224 |
| | testosterone resistance, 225 |
| | typical case history, 223–224 |
| | mammographic breast density, 175 |
| | effects of estrogen/progestin HRT, 130 |
| | Marker, Russell, 24 |
| | Mayo Clinic Cohort Study of Oophorectomy and Aging, 216–217 |
| | medroxyprogesterone acetate (MPA), 131 |
| | cardiovascular effects, 43 |
| | memory effect of estrogen therapy at menopause, 92 |
| | effects of HRT, 208 |
| | potential benefits of estrogen at menopause, 98 |
| | role of the cholinergic system, 99 |
| | role of the dopaminergic system, 94 |
| | role of the serotonergic system, 94 |
| | <i>See also</i> Alzheimer's disease (AD). |
| | memory loss, 8 |
| | menopausal symptoms and CVD risk, 38–39 |
| | approach to investigation and treatment, 32–34 |
| | back pain, 8 |
| | breast tenderness, 8 |
| | changes in sexuality, 8 |
| | classification, 30 |
| | definition, 29 |
| | depression, 8, 31–32 |
| | differential diagnosis, 32 |
| | dyspareunia, 7–8 |
| | headache, 8, 31 |
| | insomnia, 31 |
| | irritability, 8 |
| | joint pain, 31 |
| | joint stiffness, 8 |
| | loss of libido, 8 |
| | memory loss, 8 |
| | menorrhagia, 8 |
| | migraine, 8, 31 |
| | neuromuscular symptoms, 31 |
| | palpitations, 8 |
| | physical symptoms, 7–8 |
| | poor concentration, 8 |
| | psychogenic symptoms, 31–32 |
| | psychological symptoms, 8 |
| | range of symptoms, 6 |
| | restless leg syndrome, 8 |
| | scoring system, 32 |
| | sleep disturbance, 8 |
| | urge incontinence, 32 |
| | urogenital symptoms, 7, 32 |
| | vaginal problems, 32 |
| | variation in frequency and severity, 30 |
| | <i>See also</i> vasomotor symptoms. |
| | menopausal transition and osteoporosis, 9 |
| | and weight gain, 8–9 |
| | approach to diagnosis, 32–34 |
| | breast cancer risk, 9 |
| | case example, 29, 32–34 |
| | changes associated with, 1 |
| | definition, 29 |
| | endometrial cancer risk, 9 |
| | loss of bone mineral density, 9 |
| | physiological basis, 29–30 |
| | physiological changes, 3–6 |
| | physiological consequences, 8–9 |
| | risk of cardiovascular disease, 8–9 |
| | risk of hypertension, 8–9 |
| | risk of insulin resistance, 8–9 |
| | risk of metabolic syndrome, 8–9 |
| | menopause cause of, 11 |
| | consequences of follicle depletion, 11 |

- definition, 3, 29
- factors influencing onset, 1
- menopause experience
 - effects of beliefs about, 81–82
- menorrhagia, 8
- menstrual cycle
 - hormonal regulation, 1–3
- metabolic impact of
 - progestogens, 127
- metabolic syndrome
 - risk related to menopause, 8–9
- mifepristone, 125
- migraine, 8, 31
- Million Women Study (MWS), 26, 174
 - endometrial effects of HRT, 175
- mirabegron, 49
- Mirena™, 34, 165, 169, 176
- mood disorders
 - effects of HRT, 207
- Morgentaler, Abraham, 229
- motherwort herbal remedy, 22
- mumps infection, 195
- muscles
 - changes related to the menopause, 62
 - effects of HRT, 62
 - recommendations for maintenance, 62
- musculoskeletal system
 - benefits and risks of HRT, 62–65
- myocardial infarction in women, 36
- myomectomy, 115
- neuralgias (gynecological), 116
- neurodegenerative disease risk
 - effects of HRT, 208
- neuromuscular symptoms, 31
- neurotransmitters
 - effects of hormones, 8
- night sweats. *See* vasomotor symptoms
- non-hormonal treatments
 - black cohosh, 154
 - case example, 149
 - clonidine, 150–151
 - concern about HRT, 149
 - considerations when recommending, 149
 - evening primrose oil, 154
 - exercise, 155
 - gabapentin, 153
 - lifestyle modifications, 155
 - non-pharmacological therapies, 153–155
 - overview of current evidence, 155–156
 - pathophysiology of hot flashes, 149–156
 - pharmacological preparations, 150–153
 - phytoestrogens, 153–154
 - selective serotonin reuptake inhibitors (SSRIs), 152–153
 - stellate ganglion blockade, 131
 - symptoms associated with perimenopause, 149
 - symptoms related to estrogen deficiency, 149
 - vitamin E, 154
- noradrenaline
 - role in hot flashes, 156
- norethisterone, 134
- norethisterone acetate (NETA), 43
- norethynedrel, 174
- North American Menopause Society (NAMS), 124, 163
- Nurses' Health Study (NHS), 39, 139
- NuvaRing™, 171
- obesity
 - and CVD risk, 36
 - and the menopausal transition, 8–9
 - risk factor for VTE, 185
- odanacatib, 79
- oocytes
 - antral follicle structure, 2
 - insuring against loss, 17–18
 - production, 5
 - vitrification, 17–18
- oophorectomy, 30, 59, 105, 150, 216–217
- ormeloxifene, 142
- Ortho-Evra™, 171
- Orwell, George, 25
- ospemifene, 57, 76, 142, 144–145
 - effect on bone, 145
 - effect on breast, 145
 - effect on endometrium, 145
- osteonecrosis of the jaw (ONJ), 77
- osteopenia, 69
- osteoporosis, 32
 - assessment of falls risk, 68
 - association with postmenopause, 58
 - bone mineral density (BMD) assessment, 68–70
 - clinical assessment, 67–68
 - clinical case (osteopenia), 71
 - clinical case (osteoporosis and fracture risk), 71
 - diagnosis, 68–70
 - differential diagnosis, 67
 - dual energy X-ray absorptiometry (DXA), 68–70
 - effects of decrease in estrogen, 58–59
 - effects of POI, 217
 - features of postmenopausal osteoporosis, 67
 - fracture risk stratification, 70
 - height loss, 67
 - laboratory investigations, 70–72
 - nature of fractures, 68
 - pathophysiology, 58–59
 - postmenopausal bone remodeling, 58–59
 - prevention of postmenopausal bone loss, 65
 - risk factors, 67
 - risk related to the menopause, 9
- osteoporosis management
 - alternatives to HRT, 65
 - bazedoxifene, 65, 76
 - benefits and risks of HRT, 62–65
 - bisphosphonates, 65, 76–77
 - bone pathophysiology, 73–74
 - calcitonin, 65
 - calcitriol, 65
 - case example, 73, 80
 - denosumab, 78–79
 - general management, 74
 - hormone replacement therapy (HRT), 59–60, 74–75, 207
 - novel therapies under development, 79
 - parathyroid hormone (PTH), 77–78

| 240 | Index |
|---|--|
| osteoporosis management (cont.) <ul style="list-style-type: none">pharmacological<ul style="list-style-type: none">interventions, 74–79raloxifene, 65, 75, 144recommendations, 79selective estrogen receptor modulators (SERMs), 65, 75–76strontium ranelate, 65, 78teriparatide, 65, 77–79therapeutic options, 74tibolone, 65, 75vitamin D/calcium, 65 osteoporotic compression fractures, 59–62 | ovarian tissue cryopreservation, 18 |
| osteoporotic fractures, 68 <ul style="list-style-type: none">consequences of, 67low-trauma fracture, 67 ovarian cancer, 109, 111 <ul style="list-style-type: none">and HRT, 176–177, 212risk in BRCA1 and BRCA2 mutation carriers, 177–178survivors and HRT, 181–182 ovarian cysts, 108 <ul style="list-style-type: none">management, 116pathophysiology, 110–111simple ovarian cysts, 110–111solid or complex ovarian cysts, 111 ovarian epithelial cancer, 170 | ovarian volume, 16 |
| ovarian follicles <ul style="list-style-type: none">antral follicles, 2consequences of follicle depletion, 11development of primordial follicles, 11loss of, 3–6production of reproductive hormones, 11variation in numbers in ovaries, 11–12variation in rates of loss, 11–12 ovarian reserve <ul style="list-style-type: none">and reproductive lifespan, 11–12assessment using AMH levels, 14definitions, 13–14establishment during fetal life, 11–13measurement of, 12–15rates of loss of follicles, 11–13 | ovulation, 2 |
| | oxybutynin, 49 |
| | palpitations, 8 |
| | panax ginseng herbal remedy, 22 |
| | parathyroid hormone (PTH), 60, 77–78 |
| | paroxetine, 31, 152 |
| | pelvic floor muscle exercises, 48 |
| | pelvic floor myalgia, 116 |
| | pelvic mass, 114 |
| | pelvic organ dysfunction <ul style="list-style-type: none">case study, 45, 50causes, 45prevalence, 45role of estrogen, 46role of progesterone, 46role of the menopause, 45types of disorders, 45 |
| | pelvic organ prolapse <ul style="list-style-type: none">conservative management, 47–48cystocele, 46–47enterocele, 46–47local estrogen therapies, 48pelvic floor muscle exercises, 48pessaries, 48prevalence, 45–47procidentia, 46–47rectocele, 46–47risk factors, 46surgical management, 49symptoms, 46–47types of disorder, 46–47uterine prolapse, 46–47 |
| | Pelvic Organ Prolapse Quantification System (POP-Q), 45–46 |
| | percutaneous tibial nerve stimulation, 49 |
| | perimenopause <ul style="list-style-type: none">definition, 3, 29, 163 |
| | pessaries, 48 |
| | physical symptoms of the menopausal transition, 7–8 |
| | phytoestrogens, 23, 57, 122–123, 153–154, 158, 160 |
| | phytosterols, 158, 160 |
| | pituitary gland <ul style="list-style-type: none">hormones produced by, 2inhibition of FSH secretion, 2 |
| | plant sources of estrogens, 122–123 |
| | PLISSIT model, 106 |
| | politics of postmenopausal sexuality, 23–24 |
| | polycystic ovary syndrome, 14, 16, 139 |
| | positron emission tomography (PET) of the brain, 95 |
| | postmenopausal sexuality <ul style="list-style-type: none">changing views of, 23–24social issues, 23–24 |
| | postmenopause <ul style="list-style-type: none">definition, 3, 29 |
| | prebiotics, 159–160 |
| | predicting the menopause <ul style="list-style-type: none">antral follicle count (AFC), 16definitions of ovarian reserve, 13–14effects of chemotherapy, 14–17in women at risk of POI, 16–17influence of the ovarian reserve, 11–12measurement of ovarian reserve, 12–15reproductive lifespan, 11–12role of AMH, 14–16social fertility preservation, 11use of AMH, 16–17 |
| | Premarin [®] , 24–25, 27, 118–119, 122 |
| | premature menopause. <i>See</i> premature ovarian insufficiency (POI) |
| | premature ovarian insufficiency (POI), 16–17 <ul style="list-style-type: none">and autoimmune disease, 218and cardiovascular disease, 217and life expectancy, 216and osteoporosis, 217and risk of cognitive impairment, 217assessment and investigations, 217–218case example, 193, 203, 215–217, 219–220 |

| | | Index | 241 |
|--|--|---|-----|
| causes of POI, 193–195, 215–216 | role in pelvic organ dysfunction, 46 | factors affecting experience of the menopause, 81, 89 | |
| chance of spontaneous ovulation and pregnancy, 196 | role in the menstrual cycle, 2 | hormonal effects at menopause, 81 | |
| contraception, 219 | progesterone receptors (PRs), 124 | influence of beliefs about menopause, 81–82 | |
| counseling and emotional support, 219 | action of progestins, 124–125 | relationship between menopause and mood, 82–85 | |
| definition, 193 | isoforms, 125 | risk factors for depressed mood, 82–85 | |
| egg donation procedure, 196–202 | progestin-only contraception routes of administration, 168–169 | vasomotor symptoms and mood, 85–86 | |
| fertility, 193, 220 | progestin-only pill (POP), 165–166 | psychological symptoms of the menopausal transition, 8 | |
| fertility treatment, 196 | progestins | psychosocial context of the menopause, 81–82 | |
| follicle-stimulating hormone (FSH) levels, 215 | action in the endometrium, 127–128 | puerperal psychosis, 94 | |
| genetic causes, 218 | binding to progesterone receptors, 124–125 | pulmonary embolism, 184 | |
| hormone replacement therapy (HRT), 195, 219–220 | binding to steroid hormone receptors, 124–125 | <i>See also</i> venous thromboembolism (VTE). | |
| incidence, 216 | cardiovascular effects in HRT, 43 | quantitative computed tomography (QCT), 69 | |
| initial assessment and diagnosis, 193–195 | definition, 124 | Quick Screen tool, 68 | |
| integrated approach to care, 217 | estrogen/progestin regimes in HRT, 128–129 | radiotherapy and premature ovarian insufficiency (POI), 195 | |
| long-term health issues, 216–217 | evidence for effects in HRT, 130–134 | menopause induced by, 30 | |
| luteinizing hormone (LH) levels, 215 | HRT effects on mammographic breast density, 130 | risk of vulvo-vaginal atrophy, 55 | |
| management, 195–196 | role in HRT, 124 | raloxifene, 65, 75, 142 | |
| multidisciplinary care, 217 | progestogens | conditions approved for, 144 | |
| need for a POI registry, 220–221 | definition, 124 | effect on bone, 144 | |
| need for better understanding of POI, 222 | development of treatments, 25 | effect on breast, 144 | |
| primary, 215 | evidence for effects in HRT, 130–134 | effect on endometrium, 144 | |
| secondary, 215 | mechanism of action, 124–125 | effect on vasomotor symptoms, 144 | |
| social fertility preservation, 215–216 | metabolic impact, 127 | rectocele. <i>See</i> pelvic organ prolapse | |
| symptoms, 215–216 | Promensil, 153 | relaxation therapies, 157, 159–160 | |
| premenopause | Provera (medroxyprogesterone acetate), 25, 27 | reproductive aging definitions, 3 | |
| definition, 2 | pseudo-menopause, 96 | staging systems, 3 | |
| premenstrual syndrome, 31 | psychogenic symptoms, 31–32 | reproductive lifespan link to ovarian reserve, 11–12 | |
| risk of menopausal symptoms, 85 | psychological perspective | restless leg syndrome, 8 | |
| primordial follicles | approach to treatment of menopausal symptoms, 89 | risedronate, 76–77 | |
| development of, 11 | biopsychosocial approach, 81, 86–87 | romosozumab, 79 | |
| probiotics, 159–160 | case example (depression), 81, 86–87, 89 | | |
| procidentia. <i>See</i> pelvic organ prolapse | CBT interventions for menopausal symptoms, 85–90 | | |
| progesterone | context of the menopause, 81 | | |
| development of bio-identical treatments, 25 | | | |
| levels in the menopausal transition, 6 | | | |

| 242 | Index | |
|-----|--|--|
| | sacral neuro-modulation, 49 | |
| | sage leaf herbal remedy, 22 | |
| | salvia root in herbal medicine, 22 | |
| | sclerostin antibodies, 79 | |
| | scopolamine, 96 | |
| | Selective Estrogen Menopause and Response to Therapy (SMART) trials, 145–146 | |
| | selective estrogen receptor modulators (SERMs), 57, 65, 75–76, 176 | |
| | case example (menopausal symptoms), 142 | |
| | clinical uses for postmenopausal women, 142 | |
| | description, 142 | |
| | mechanism of action, 143 | |
| | ospemifene, 144–145 | |
| | potential benefits for postmenopausal women, 143, 146–147 | |
| | raloxifene, 144 | |
| | tamoxifen, 143 | |
| | tissue selective estrogen complex (TSEC), 145–146 | |
| | toremifene, 143–144 | |
| | types available for postmenopausal use, 142–146 | |
| | selective progesterone receptor modulators (SPRMs), 125 | |
| | selective serotonin reuptake inhibitors (SSRIs), 152–153 | |
| | selective tissue estrogenic activity regulator (STEAR), 174 | |
| | serotonergic system role in mood and memory, 94 | |
| | serotonin role in hot flashes, 156 | |
| | serotonin-norepinephrine reuptake inhibitors (SNRIs), 103 | |
| | sertraline, 152 | |
| | sex hormone binding globulin (SHBG), 137–138, 224 | |
| | sexual disorders aging and sexual decline, 104 | |
| | and the female sexual response cycle, 104 | |
| | and the menopause, 102–103 | |
| | approach to management, 104–106 | |
| | arousal disorder, 103 | |
| | causes, 103 | |
| | desire disorder, 103 | |
| | DSM-V classification, 103 | |
| | duration, 103 | |
| | dyspareunia, 103 | |
| | hormonal impact at menopause, 104 | |
| | loss of libido, 8, 102, 104–106 | |
| | non-coital pain disorders, 103 | |
| | orgasmic disorders, 103 | |
| | PLISSIT model, 106 | |
| | vaginismus, 103 | |
| | sexuality changes related to the menopause, 8 | |
| | Sheehy, Gail, 224 | |
| | simple ovarian cysts pathophysiology, 110–111 | |
| | single photon emission computed tomography (SPECT) of the brain, 97 | |
| | skin benefits of HRT, 207–208 | |
| | cancers and HRT, 167 | |
| | sleep problems, 8 | |
| | cognitive behavior therapy (CBT), 88 | |
| | smoking and VTE risk, 187 | |
| | risk factor for CVD, 36 | |
| | social context of menopause, 81–82 | |
| | social egg freezing, 17–18 | |
| | social fertility preservation, 11, 215–216 | |
| | social issues postmenopausal sexuality, 23–24 | |
| | solid or complex ovarian cysts pathophysiology, 111 | |
| | solifenacin, 49 | |
| | St John's wort (<i>Hypericum perforatum</i>), 22 | |
| | staging systems for reproductive aging, 3–5 | |
| | STAR trial, 143 | |
| | stellate ganglion blockade, 155 | |
| | steroid hormone receptors action of progestins, 124–125 | |
| | Stockholm Study, 179–180 | |
| | stomach cancer and HRT, 179, 209 | |
| | STRAW+10 staging system, 3, 7 | |
| | stress incontinence possible mechanism, 46 | |
| | stress urinary incontinence conservative management, 48–49 | |
| | pessaries, 48 | |
| | risk factors, 46 | |
| | surgical management, 50 | |
| | symptoms, 47 | |
| | See also incontinence. | |
| | stroke risk and HRT, 26–27, 211 | |
| | strontium ranelate, 65, 78 | |
| | structural magnetic resonance imaging (sMRI) of the brain, 94–95 | |
| | Studd, Professor John, 228 | |
| | surgical menopause, 85 | |
| | tamoxifen, 56, 76, 111, 115, 142, 152 | |
| | cancer risk, 176 | |
| | concerns and adverse effects, 143 | |
| | conditions approved for, 143 | |
| | interactions with SSRIs, 152–153 | |
| | teratoma, 111 | |
| | teriparatide, 65, 77–79 | |
| | testosterone, 2 levels during the menopausal transition, 6 | |
| | testosterone replacement therapy (TRT) for male menopause, 223–224 | |
| | for women, 105 | |
| | See also androgen therapy. | |
| | theca cells, 2 | |
| | thermoneutral zone, 85, 150 | |
| | thrombophilia effects of HRT on VTE risk, 187–188 | |
| | tibolone, 65, 75, 136–137, 142, 174, 186 | |
| | Tilt, John, 22 | |
| | Timed Up and Go test, 68 | |

- tissue selective estrogen complex (TSEC), 76, 142, 145–146, 176
- adverse events, 146
- effect on bone loss prevention, 145
- effect on breast, 146
- effect on endometrium, 146
- effect on vagina, 146
- effect on vasomotor symptoms, 145
- tolterodine, 49
- toremifene, 76, 142
- uses in postmenopause, 143–144
- tranexamic acid, 114
- transdermal delivery systems
- contraceptive patches, 170–171
- estrogen therapy, 42, 105, 122
- HRT delivery, 134
- tribulus herbal remedy, 22
- tropium XL, 49
- Type II diabetes risk and HRT, 209
- UK Androgen Study (UKAS), 229
- ulipristal, 125
- ulipristal acetate, 115, 169
- upper GI tract cancer and HRT, 159
- urethral bulking injections, 50
- urge urinary incontinence, 32
- conservative management, 48–49
- risk factors, 46
- surgical management, 50
- symptoms, 47
- See also* incontinence.
- urinary tract infections, 7, 52
- urine-derived estrogens, 118–119
- urine-derived estrone, 118
- urogenital symptoms, 7, 32
- effects of HRT, 206
- prevalence in postmenopausal women, 45
- See also* incontinence; pelvic organ dysfunction.
- US Endocrine Society, 140
- uterine artery embolization (UAE), 115
- uterine bleeding, abnormal, 108, 113
- uterine prolapse. *See* pelvic organ prolapse
- Uterogestan[®], 34
- Vagifem[®], 48
- vagina
- dryness. *See* vulvo-vaginal atrophy
- pH evaluation, 54
- problems related to estrogen deficiency, 32
- vaginal cancer survivors and HRT, 182
- vaginal maturation index (VMI), 54, 144
- vaginal ring contraceptive, 170–171
- vascular function
- modulation by estrogens, 37–38
- vasomotor symptoms, 7–8, 30–31
- cognitive behavior therapy (CBT), 88–89
- duration of symptoms, 30
- effects of HRT, 206
- effects of lifestyle modifications, 155
- effects of TSEC, 145
- exercise interventions, 155
- mechanism of hot flashes, 30–31
- non-hormonal
- pharmacological treatments, 150–153
- non-pharmacological therapies, 153–155
- pathophysiology of hot flashes, 149–156
- raloxifene side effects, 144
- relationship with mood, 85–86
- stellate ganglion blockade, 131
- venlafaxine, 31, 152–153
- venous thromboembolism (VTE)
- description, 184
- gender differences in incidence, 185
- genetic and acquired risk factors, 183–185
- risk with hormonal contraception, 166–167
- venous thromboembolism (VTE) and HRT, 211–212
- age risk factor, 185
- case example, 190–191
- effect of routes of administration, 186
- effects of length of use, 187
- effects of smoking, 187
- health risks for women, 183
- mechanism of HRT-induced VTE, 188–189
- obesity risk factor, 185
- specific risk of HRT, 185–186
- thrombophilia, 187–188
- weighing risks against benefits, 189–190
- women with personal history of venous thrombosis, 188
- Virchow's triad, 183
- vitamin B6 supplementation, 159, 160
- vitamin D supplementation, 160
- vitamin D/calcium supplementation, 158
- osteoporosis treatment, 65
- vitamin E treatment, 154
- vitamin K supplementation, 158, 160
- vitex (chaste tree) herbal remedy, 22
- voxel-based morphometry (VBM), 95
- vulval cancer survivors and HRT, 182
- vulvodynia, 103
- vulvo-vaginal atrophy (VVA)
- changes related to the menopause, 53–54
- chronic nature of, 53–54
- clinical vignette, 52
- definition, 52
- effects of HRT, 55
- health-care strategy, 57
- investigation and treatment, 52–53
- local estrogen therapy, 55–56
- recognizing symptoms and signs, 54–55
- symptoms, 52–53
- treatment options, 55–57
- under-reporting and under-recognition, 52–53

| 244 | Index | |
|--|--|--|
| weight gain and the menopausal transition, 8–9 in perimenopausal women, 36 Wilson, Dr Robert A., 25, 118–119 WISDOM Study, 186 witchcraft association with post- menopausal women, 21 Women’s Estrogens for Stroke Trial (WEST), 39 Women’s Health Initiative (WHI) Study, 25–28, 40, 142 | breast cancer risk and HRT, 173–174 colorectal cancer risk, 178 consequences of study conclusions, 27–28, 123 controversy over interpretation of results, 26–27 effects of progestins in HRT, 130–133 endometrial effects of HRT, 175 HRT and osteoporosis, 74–75 lung cancer risk, 178 | modern interpretation of findings, 40–41 negative consequences for male TRT, 228 ovarian cancer risk, 176 prevalence of pelvic organ prolapse, 45–46 re-evaluation of data, 62–65 skin cancer risk, 167 VTE risk and HRT, 185 yoga, 157, 159–160 zoledronate, 76–77 |